There was a problem adding this course to your account. Please try again in a few minutes. If the problem persists, you can contact our support department at (877) 880-1335.
Adding Registration, Please wait...
You must be logged in to perform this action.
Log in
Cancel
Practical Impact of SCOTUS’s decision in Helsinn v. Teva on Secret Sales
Intellectual Property Law Section, Patent Interest Group
In Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., the U.S. Supreme Court affirmed the Federal Circuit’s interpretation of the “on sale bar” — holding that “Congress did not alter the meaning of ‘on sale’ when it enacted the AIA.” In so doing, the Supreme Court answered affirmatively that a secret sale of an invention, or a sale of a technology under terms that require the invention to remain confidential, is barred under 35 U.S.C. § 102(a)(1), thereby preventing the invention from being patented. In this webinar, our panelists will weigh in on the impact of this decision and offer practical pointers to stakeholders and practitioners when dealing with secret, on-sale offers, activities, or commercialization.
0.75 Participatory MCLE Credits
Customers Who Bought This Item Also Bought
(CLEtoGo (Podcasts)) 2018 IP Institute: The USPTO and American Innovation
(OnDemand) 2018 IP Institute: Legal Ways of Getting Paid for Music in The Digital Era
(OnDemand) Got Priority? What you need to know to avoid pitfalls and loss of priority rights in Europe
(OnDemand) The End of Life Option Act: How it Works In The Real World
(CLEtoGo (Podcasts)) Antitrust Implications of Healthcare Provider Consolidation
(OnDemand) 45th Annual IP Institute: The Changing Climate on Pharma Patents, Healthcare Investment, and Drug Pricing & Accessibility
We are committed to accessibility! All OnDemand programs after January 1, 2022 include closed captioning. To request closed captioning for a program older than January 1, 2022, send us a note at accessibility@calawyers.org or contact us at 916-516-1760 for assistance.